Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis


  • Elevated plasma neurofilament light chain (pNfL) levels may be used as a prognostic marker and treatment monitoring tool for assessment of risk of permanent disability in patients with multiple sclerosis (MS).

Why this matters

  • It is often difficult to forecast the long-term prognosis in patients with MS due to the highly variable interpatient disease course.

  • Prognostic biomarkers can aid treatment decisions, particularly at the early stages of the disease.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.